HIV molecular epidemiology and new treatment strategies in Russia and Eastern Europe

Leading partner organisation: Karolinska Institute (Sweden)

Adopting a comprehensive approach to the management of HIV infection, CARE will on one hand analyse the molecular epidemiology of the infection, including treatment efficacy and drug resistance; on the other hand, it will prepare for the introduction of dolutegravir-based treatment, as recommended by the World Health Organisation.

CARE will pursue the following specific objectives:

  • Characterization of HIV transmission clusters with different subtypes and recombinants, including molecular epidemiology of HIV/TB coinfection across Europe and the Russian Federation

  • Development of high throughput sequencing (HTS) protocols based on next generation sequencing for monitoring HIV drug resistance in a convenient and productive format

  • Analysis of the mechanisms of INSTI (integrase strand transfer inhibitor) drug resistance in the highly prevalent HIV-1 subtype A6, including the role of natural polymorphisms and off-target mechanisms based on mutations outside the integrase gene

  • Comparative analysis of time trends of pre-treatment drug resistance in Russia and estimation of its effect on upcoming dolutegravir-based therapy, based on both currently available data and a specific PDR surveillance program

  • Analysis of adverse events, tolerability, and treatment efficacy of DTG, including HIV drug resistance assessment, in a large cohort of patients from Europe and Russia including both HIV-monoinfected and HIV/TB coinfected patients

Heading 1

Heading 1

Heading 1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.

Subscribe to the CARE newsletter

Francesca Incardona